Data publication: Development and Evaluation of Deuterated [18F]JHU94620 Isotopologues for the Non-invasive Assessment of the Cannabinoid type 2 Receptor in Brain

What is already known • Increased expression of the CB2R in the brain is linked to certain neuropathological diseases. • First clinical trials for CB2R-directed therapies are conducted. What this study adds • [18F]JHU94620-d8 provides the potential to quantify the CB2R receptor density in the brain by positron-emission-tomography. Clinical significance • Stratification of patients for CB2R-directed therapies and follow up of the treatment response is needed.